Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling

BACKGROUND: Pemetrexed plus platinum doublet chemotherapy regimen remains to be the standard first-line treatment for lung adenocarcinoma patients. However, few biomarkers can be used to identify potential beneficiaries with maximal efficacy and minimal toxicity. This study aimed to explore potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Wei-Jing, Cao, Peng, Zhang, Qi-Lin, Han, Xiao-Yu, Wang, Shuo-Wen, Huang, Yi-Fei, Wu, San-Lan, Li, Qiang, Zhang, Rui, Xu, Shuang-Bing, Liu, Ya-Ni, Shi, Shao-Jun, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918859/
https://www.ncbi.nlm.nih.gov/pubmed/35290920
http://dx.doi.org/10.1016/j.tranon.2022.101393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918859/
https://www.ncbi.nlm.nih.gov/pubmed/35290920
http://dx.doi.org/10.1016/j.tranon.2022.101393

Ejemplares similares